Compare Heron Therapeutics Inc (HRTX) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Rocket Lab USA Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Rocket Lab USA Inc trades at $68.21 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 643.1× Heron Therapeutics Inc's market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Rocket Lab USA Inc for 29 Days on average.
| HRTX | RKLB | |
|---|---|---|
Market Cap | $68.01M | $43.74B |
Volume | 1,891,941 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $1.49 | $150.23 |
52-Week Low | $0.27 | $39.48 |
Typical Hold Time | 35 Days | 29 Days |
Enterprise Value | $174.75M | $41.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Rocket Lab (RKLB) trades at $68.40, down 4.89% amid a bearish technical signal. The company shows strong revenue growth with $602M in 2025 and $769M projected for 2026, though it remains unprofitable with a -21.51% net margin. Recent positive developments include securing its largest-ever commercial Electron launch contract with Synspective, expanding the backlog to over 100 missions. Analyst sentiment remains bullish with a $107 consensus price target despite current losses.
The outlook balances significant growth potential against persistent profitability challenges. Investment opportunity lies in Rocket Lab's expanding launch backlog and market position, while risks include intense competition from SpaceX, high valuation multiples, and ongoing cash burn. The stock's current technical weakness contrasts with strong fundamental growth prospects and Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
